ArticleBMC endocrine disorders2025
Lower hemoglobin levels may increase the risk of diabetic retinopathy in patients with type 2 diabetes mellitus.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study explored the correlation between hemoglobin (HB) and diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM), and the potential impact of disease duration.
methodsData were collected from the National Health and Nutrition Examination Survey (NHANES) (2001–2018) and the National Metabolic Management Center (MMC) of Fujian Medical University Union Hospital (2018–2023). DR risk factors were identified by univariate analysis. The HB-DR correlation was explored by multivariate logistic regression and analyzed by generalized additive model and smoothed curve fitting. The impact of diabetes mellitus (DM) duration on the correlation was examined by interaction tests.
resultsData of 5,089 and 1,893 participants were respectively recruited from the NHANES and MMC databases. In both databases, HB levels were negatively correlated with DR. In the MMC, the negative association persisted in subgroup stratification of sex, age, and body mass index, with the normal weight group reporting a U-shaped relationship at an inflection point of 12.7 (g/dL). The interaction between DM duration and HB significantly impacted the DR probability.
conclusionsDM duration may impact the association between HB and DR risk and a low HB level indicates a significant DR risk in patients with T2DM, especially in those with a short DM duration, highlighting the necessity of hemoglobin detection and anemia intervention in the treatment of patients with T2DM. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.